A recombinant adenovirus of PEDVS chimeric protein and its preparation method and use

By designing and constructing a recombinant adenovirus of PEDVS chimeric protein, the problem that existing vaccines are difficult to induce broad-spectrum mucosal immune antibodies is solved, and the effect of stimulating piglets to produce IgA antibodies through oral immunity is achieved, providing better protective effects.

CN118667886BActive Publication Date: 2024-11-08SICHUAN HUASHEN ANIMAL BIOLOGICAL PRODS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411156178.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-08
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

Existing PEDV vaccines are difficult to induce the production of broad-spectrum mucosal immune antibodies, especially in piglets, which are difficult to immunize by oral treatment. Inactivated vaccines and attenuated vaccines on the market cannot induce the production of IgA antibodies, resulting in limited protection effect.

Method used

Develop a recombinant adenovirus of PEDVS chimeric protein. By designing and constructing sequences expressing PEDVS proteins, the fusion protein contains amino acid sequences of G2 and G1 strains, combining Fibritin_C polypeptide and Flag tags, the recombinant adenovirus system is used in HEK Prepare and purify the cells to form stable trimer proteins for the preparation of vaccines.

Benefits of technology

This vaccine can immunize animals through oral or intramuscular injection, induce the production of broad-spectrum SIgA antibodies, and provide better immune protection effects, especially in piglets, which can stimulate the production of IgA antibodies, surpassing the protective effects of traditional vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118667886B_ABST
    Figure CN118667886B_ABST
Patent Text Reader

Abstract

The present invention provides a recombinant adenovirus of a PEDVS chimeric protein and a preparation method and use thereof, belonging to the field of gene recombination technology, and the preparation method specifically comprises the following steps: Step 1: design of PEDVS chimeric protein and construction of transfer vector; Step 2: construction of recombinant adenovirus; Step 3: small-scale preparation and purification; wherein, in step 1, the specific steps are as follows: according to PEDV epidemiological data, artificially design a sequence capable of expressing PEDVS protein and perform codon optimization, the nucleotide is shown in SEQ ID NO.1, and the fusion protein sequence is shown in SEQ ID NO.2. The present invention mainly provides a PEDV vaccine capable of inducing immune animals to produce broad-spectrum mucosal immune antibodies, providing a scientific means for the prevention and control of PEDV infection in clinical practice.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene recombination technology, and in particular to a recombinant adenovirus of a PEDVS chimeric protein and a preparation method and use thereof. Background Art

[0002] PEDV (Porcine Epidemic Diarrhea virus, PEDV) can infect pigs of all ages. The younger the susceptible pigs are, the more severe the disease is and the higher the mortality rate is. The mortality rate of suckling piglets under 10 days old can be as high as 100%. Clinical epidemiological studies have found that PEDV, which is prevalent in my country, is the main pathogen of piglet diarrhea, and PEDV infection has been detected in more than 50% of diarrhea cases. Molecular epidemiological studies have found that there are currently multiple epidemic diarrhea virus strains in my country. According to the sequence characteristics of the PEDV S gene, the PEDV epidemic strains can be divided into G1 and G2 genotypes. The G1 and G2 genotypes can be further subdivided into G1a, G1b, G1c, G2a, G2b, G2c and other genotypes. Another type of PEDV strains are divided into S-INDEL strains and Non S-INDEL strains based on the PEDV full genome sequence and S gene deletion and insertion mutations. Currently, the G2 epidemic strain accounts for more than 70%. Highly immune sera were prepared using different genotype strains for cross-neutralizing antibody testing. The test results showed that although different serotypes have neutralizing effects, the differences are large. Therefore, vaccines prepared from a single strain are difficult to induce broad-spectrum immunity.

[0003] PEDV is mainly transmitted through the fecal-oral route. The morbidity and mortality rates are highest in suckling piglets after infection. The younger the age, the higher the morbidity and mortality rates. However, it is difficult for piglets at this stage to establish active immunity. Therefore, the prevention and control of PEDV in suckling piglets mainly depends on the maternal antibodies of the sow, among which the level of IgA antibodies in breast milk is positively correlated with the protective effect.

[0004] However, the inactivated vaccines and attenuated vaccines currently on the market cannot induce the production of mucosal immune antibodies in the immunized pigs. Therefore, the development of a new vaccine that can induce the production of IgA antibodies has important clinical value for the prevention and control of PEDV. Summary of the invention

[0005] The purpose of the present invention is to provide a recombinant adenovirus of PEDV S chimeric protein and its preparation method and use, which is mainly a PEDV vaccine that can induce immune animals to produce broad-spectrum mucosal immune antibodies, providing a scientific means for the prevention and control of PEDV infection in clinical practice.

[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is:

[0007] A method for preparing a recombinant adenovirus of a PEDVS chimeric protein comprises the following steps:

[0008] Step 1: Design of PEDVS chimeric protein and construction of transfer vector;

[0009] Step 2: Construction of recombinant adenovirus;

[0010] Step 3: Preparation and purification of recombinant virus;

[0011] Among them, in step 1, the specific steps are as follows:

[0012] According to the epidemiological data of PEDV, a sequence capable of expressing PEDVS protein was artificially designed and codon optimized. The nucleotide sequence is shown in SEQ ID NO.1, and the fusion protein sequence is shown in SEQ ID NO.2.

[0013] In some specific implementation examples, in step 1,

[0014] Positions 1-22 of the fusion protein are secretion signal peptides: MDAMKRGLCCVLLLCGAVFVSN;

[0015] The amino acid sequence at positions 23-761 was derived from the PEDV G2 strain;

[0016] The amino acid sequence at positions 762-1326 is derived from the PEDV G1 strain

[0017] GSG connecting peptide at positions 1327-1329;

[0018] The polypeptide at positions 1330-1354 is derived from the Fibritin_C polypeptide of Tequatrovirus T4, which allows the protein containing this sequence to form a stable trimer, the GSG connecting peptide at positions 1355-1357, the Flag tag protein at positions 1358-1365, and the polypeptide that promotes protein expression at positions 1366-1372;

[0019] The above sequence was optimized according to the codon characteristics of pigs to obtain the nucleotide sequence expressing the fusion protein, which was synthesized after adding a stop codon at the end of the sequence and cloned between the EcoRⅠ and HindⅢ restriction sites of the pDC316 vector. The plasmid with correct sequencing was named pDC316-SQ.

[0020] In some specific implementation examples, the specific steps of step 2 are as follows:

[0021] HEK 293A cells were subcultured to well plates using conventional methods. On the second day after subculture, transfection was performed using a transfection reagent according to the operating instructions to co-transfect 1ug of pDC316-SQ and pBHGloxdelE13cre plasmids. After transfection, the cells were cultured in a 37°C, 5% carbon dioxide incubator. The cell status was observed daily. After cytopathic effects appeared, the cells were repeatedly frozen and thawed three times at -80°C and stored at -80°C, which was counted as ADV-PEDV SQ P1 virus.

[0022] HEK 293A cells were passaged to 10 cm culture dishes using conventional methods. When the cell confluence reached more than 90%, ADV-PEDV SQ P1 virus was inoculated and cultured in a 37°C, 5% carbon dioxide incubator using DMEM containing 2% fetal bovine serum as the maintenance medium until more than 85% of the cells showed cytopathic effects. The virus was harvested and recorded as ADV-PEDV SQ P2 virus.

[0023] In some specific implementation examples, the specific steps of step 3 are as follows:

[0024] HEK 293F cells were subcultured into 100 ml shake flasks using serum-free medium according to conventional methods, and the cell density reached 5 × 10 6 / ml was inoculated with ADV-PEDV SQ P2 virus, and after inoculation, the culture was placed at 37°C and 120rpm on an orbital shaker in a 5% carbon dioxide incubator. The cell status was observed daily and the cell viability was recorded. When the cell viability was lower than 30%, the culture bottle was placed in a -80°C refrigerator and repeatedly frozen and thawed three times, centrifuged at 12000rpm for 10 minutes, the supernatant was added to a 100KD ultrafiltration centrifuge tube, centrifuged at 4000rpm to 1 / 10 of the original volume, and then 0.1M phosphate buffer was added to the original volume, centrifuged at 4000rpm to 1 / 100 of the original volume, and finally glycerol was added at a ratio of 5:1, and the resulting aliquots were stored at -80°C, which were recorded as ADV-PEDV SQ P3 virus.

[0025] In addition, the present invention also discloses a recombinant adenovirus of a PEDVS chimeric protein, which is prepared by the above-mentioned method for preparing a recombinant adenovirus of a PEDVS chimeric protein.

[0026] In addition, the present invention also discloses a recombinant adenovirus use of a PEDVS chimeric protein, specifically for preparing a vaccine.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] The vaccine developed by the present invention can be immunized by oral administration, intramuscular injection, etc., while the existing inactivated vaccines and live vaccines cannot be immunized by oral administration; in addition, the present invention chimerizes the S proteins of strains of different genotypes, selects the main S1 protein of the G2 type epidemic strain and the S2 protein of the classic G1 type strain, so that one protein can induce antibodies against the S1 protein of the G2 type strain, and can also induce antibodies against the S2 protein of the G1 type strain, and can induce a broader spectrum of immune antibodies in immunized animals. A broad-spectrum SIgA antibody can be produced through a recombinant adenovirus system, and the immune protection effect is better. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0030] Figure 1 This is a graph showing the antibody assay results after mice were immunized with ADV-PEDV SQ P3 virus.

[0031] Figure 2 This is the result of antibody test after piglets were immunized with ADV-PEDV SQ P3 virus. DETAILED DESCRIPTION

[0032] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the embodiments of the present invention. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature. Embodiments of the present invention are described in detail below in conjunction with the accompanying drawings.

[0033] Embodiment 1

[0034] This example discloses a method for preparing a recombinant adenovirus of a PEDVS chimeric protein.

[0035] The specific steps include:

[0036] Step 1: Design of PEDVS chimeric protein and construction of transfer vector;

[0037] Step 2: Construction of recombinant adenovirus;

[0038] Step 3: Preparation and purification of recombinant virus;

[0039] Step 1: Design of PEDVS chimeric protein and construction of transfer vector:

[0040] According to the epidemiological data of PEDV, a sequence capable of expressing PEDVS protein was artificially designed and codon optimized. The nucleotide sequence is shown in SEQ ID NO.1, and the fusion protein sequence is shown in SEQ ID NO.2.

[0041] The fusion protein has a secretion signal peptide (MDAMKRGLCCVLLLCGAVFVSN) at positions 1-22, an amino acid sequence at positions 23-761 derived from the PEDV G2 strain, an amino acid sequence at positions 762-1326 derived from the PEDV G1 strain, a GSG connecting peptide at positions 1327-1329, a polypeptide at positions 1330-1354 derived from the Fibritin_C polypeptide of Tequatrovirus T4, which can form a stable trimer of the protein containing the sequence, a GSG connecting peptide at positions 1355-1357, a Flag tag protein at positions 1358-1365, and a polypeptide that promotes protein expression at positions 1366-1372. The above sequence was optimized according to the codon characteristics of pigs to obtain a nucleotide sequence expressing the fusion protein, which was synthesized by GenScript Biotech Co., Ltd. after adding a stop codon at the end of the sequence and cloned between the EcoRⅠ and HindⅢ restriction sites of the pDC316 vector. The plasmid with the correct sequencing was named pDC316-SQ.

[0042] Step 2: Construction of recombinant adenovirus:

[0043] HEK 293A cells were subcultured to 6-well plates using conventional methods. On the second day after subculture, transfection reagent Lipofectamine 3000 (purchased from Thermo Fisher Scientific China Co., Ltd.) was used to co-transfect pDC316-SQ and pBHGloxdelE13cre plasmids (purchased from Microbix Biosystems Inc.) with 1ug each according to the operating instructions. After transfection, the cells were cultured in a 37°C, 5% carbon dioxide incubator. The cell status was observed daily. After the appearance of cytopathic effect (CPE), the cells were repeatedly frozen and thawed three times at -80°C and stored at -80°C, which was counted as ADV-PEDV SQ P1 virus.

[0044] HEK 293A cells were passaged to 10 cm culture dishes by conventional methods. When the cell confluence reached more than 90%, the P1 virus was inoculated and cultured in a 37°C, 5% carbon dioxide incubator in DMEM containing 2% fetal bovine serum until more than 85% of the cells showed cytopathic effects. The virus was harvested and recorded as ADV-PEDV SQ P2 virus.

[0045] Step 3: Preparation and purification of recombinant virus:

[0046] HEK 293F cells were subcultured into 100 ml shake flasks using serum-free medium according to conventional methods, and the cell density reached 5 × 10 6 / ml was inoculated with ADV-PEDV SQ P2 virus, and after inoculation, the culture was placed at 37°C and 120rpm on an orbital shaker in a 5% carbon dioxide incubator. The cell status was observed daily and the cell viability was recorded. When the cell viability was lower than 30%, the culture bottle was placed in a -80°C refrigerator and repeatedly frozen and thawed three times, centrifuged at 12000rpm for 10 minutes, the supernatant was added to a 100KD ultrafiltration centrifuge tube (purchased from MERCK), centrifuged at 4000rpm to 1 / 10 of the original volume, and then 0.1M phosphate buffer was added to the original volume, centrifuged at 4000rpm to 1 / 100 of the original volume, and finally glycerol was added at a ratio of 5:1, and the resulting solution was packaged and stored at -80°C, which was recorded as ADV-PEDVSQP3 virus.

[0047] In actual use, the ADV-PEDV SQP3 virus content determination method is as follows:

[0048] HEK293A cells were subcultured to 96-well plates by conventional methods. 100 μl of cell suspension was added to each well, about 50,000 cells per well. Then ADV-PEDV SQ P3 virus was taken and diluted 10-fold to 10 using 2% serum DMEM. 10 , and inoculated HEK 293A cells after dilution, 8 wells were inoculated for each dilution, and cultured in a 37°C, 5% carbon dioxide incubator for 4 days.

[0049] The cultured 96-well plate was stained with immunohistochemistry according to the instructions of the Adeno-X Rapid Titer Kit (purchased from Bio-Rad Biotechnology (Beijing) Co., Ltd.), and the number of positive wells for ADV detection at each dilution was recorded. The ADV-PEDVSQ P3 virus 10 was calculated according to the Reed-Muench method. 11 TCID 50 / ml.

[0050] Furthermore, the method for determining the humoral immune effect of mice immunized with the ADV-PEDV SQ P3 recombinant virus is as follows:

[0051] Twelve 6-8 week old SPF grade BALB / C mice were purchased (Chengdu Dashuo Biotechnology Co., Ltd.) and kept in the experimental animal room of Shuke Bioengineering Co., Ltd.

[0052] Twelve mice were randomly divided into two groups. ADV-PEDV SQ P3 virus was diluted with serum-free DMEM and then injected with 10 8 TCID 50The ADV-PEDV SQ P3 virus was injected into the leg muscle, and the control group was injected with DMEM, and the injection volume was 100ul.

[0053] Serum was collected before, 2 weeks after, and 4 weeks after immunization, and S protein-specific antibodies were measured using the PEDV antibody detection kit of Nanjing Novozymes Biotech Co., Ltd., and the secondary antibody was replaced with HRP-labeled rabbit anti-mouse IgG (purchased from Sangon Biotech (Shanghai) Co., Ltd., catalog number: D110098-010).

[0054] The results of antibody determination after mice were immunized with ADV-PEDV SQ P3 virus are as follows Figure 1 shown.

[0055] Figure 1 The test results showed that the antibodies of all immunized mice became positive 2 weeks after immunization. This result indicated that the constructed recombinant virus ADV-PEDV SQP3 could stimulate mice to produce specific humoral immune responses and had the potential to prepare vaccines.

[0056] Furthermore, in actual use,

[0057] 5 The method for determining antibodies after piglets were immunized with ADV-PEDV SQP3 recombinant virus is as follows:

[0058] Twenty-five 4-week-old piglets were purchased and randomly divided into 5 groups and raised in the experimental animal room of Animal Science Bioengineering Co., Ltd.

[0059] Group 1 intramuscular injection 10 11 TCID 50 ADV-PEDV SQ P3 virus generation;

[0060] Group 2 took 10 11 TCID 50 ADV-PEDV SQ P3 virus generation;

[0061] Group 3 was injected with an equal dose of DMEM culture medium as a control;

[0062] Group 4 was immunized with commercial PEDV live vaccines, including porcine transmissible gastroenteritis and porcine epidemic diarrhea bivalent live vaccine (WH-1R strain + AJ1102-R strain);

[0063] Group 5 was immunized with commercial inactivated vaccines: porcine transmissible gastroenteritis and porcine epidemic diarrhea bivalent live vaccine (South China strain + CV77 strain).

[0064] Serum was collected before and 4 weeks after immunization, and serum IgA and IgG antibodies were measured using the PEDV antibody detection kit produced by Nanjing Novozymes Biotech Co., Ltd.

[0065] When measuring IgA antibodies, the original secondary antibody of the kit was used, and when measuring IgG antibodies, the original secondary antibody of the kit was replaced with HRP-labeled rabbit anti-pig IgG (purchased from Sangon Biotech (Shanghai) Co., Ltd., catalog number: D111051-0100).

[0066] The antibody test results (S / P value) of piglets immunized with ADV-PEDV SQ P3 virus are as follows Figure 2 As shown, in Figure 2 When the S / P value is ≥0.5, it is considered as antibody positive, otherwise it is negative.

[0067] The results showed that IgG and IgA were both positive in the oral immunization group 4 weeks after immunization, while only IgG was positive in the intramuscular immunization group, and both IgG and IgA were negative in the control group. This result shows that the ADV-PEDV SQP3 recombinant virus can induce good humoral immunity in immunized piglets, and oral immunization can stimulate piglets to produce IgA antibodies, while commercial live vaccines and inactivated vaccines cannot induce IgA antibodies.

[0068] The purpose of the present invention is to develop a PEDV vaccine that can induce immune animals to produce broad-spectrum mucosal immune antibodies, providing a scientific means for the prevention and control of PEDV infection in clinical practice. The recombinant virus can induce immune piglets to obtain good humoral immunity, and oral immunization can stimulate piglets to produce IgA antibodies, while commercial live vaccines and inactivated vaccines cannot induce the production of IgA antibodies.

[0069] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0070] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a recombinant adenovirus of a PEDV S chimeric protein, It is characterized in that The specific steps include: Step 1: Design of PEDV S chimeric protein and construction of transfer vector; Step 2: Construction of recombinant adenovirus; Step 3: Preparation and purification of recombinant virus; Among them, in step 1, the specific steps are as follows: According to the epidemiological data of PEDV, a sequence capable of expressing PEDV S protein was artificially designed and codon optimized. The nucleotide sequence is shown in SEQ ID NO.1, and the fusion protein sequence is shown in SEQ ID NO.2; In step 1, Positions 1-22 of the fusion protein are secretion signal peptides: MDAMKRGLCCVLLLCGAVFVSN; The amino acid sequence at positions 23-761 was derived from the PEDV G2 strain; The amino acid sequence at positions 762-1326 is derived from the PEDV G1 strain; Positions 1327-1329 are GSG linker peptides; The polypeptide at positions 1330-1354 is derived from the Fibritin_C polypeptide of Tequatrovirus T4, which allows the protein containing this sequence to form a stable trimer, positions 1355-1357 are GSG connecting peptides, positions 1358-1365 are Flag tag proteins, and positions 1366-1372 are polypeptides that promote protein expression; The above sequence was optimized according to the codon characteristics of pigs to obtain the nucleotide sequence expressing the fusion protein, which was synthesized after adding a stop codon at the end of the sequence and cloned between the EcoRⅠ and HindⅢ restriction sites of the pDC316 vector. The plasmid with correct sequencing was named pDC316-SQ.

2. The method for preparing a recombinant adenovirus of a PEDV S chimeric protein according to claim 1, It is characterized in that Step 2 The specific steps are as follows: HEK 293A cells were subcultured to well plates using conventional methods. On the second day after subculture, transfection was performed using a transfection reagent according to the operating instructions to co-transfect 1ug of pDC316-SQ and pBHGloxdelE13cre plasmids. After transfection, the cells were cultured in a 37°C, 5% carbon dioxide incubator. The cell status was observed daily. After cytopathic effects appeared, the cells were repeatedly frozen and thawed three times at -80°C and stored at -80°C, which was counted as ADV-PEDV SQ P1 virus. HEK 293A cells were passaged to 10 cm culture dishes using conventional methods. When the cell confluence reached more than 90%, ADV-PEDV SQ P1 virus was inoculated and cultured in a 37°C, 5% carbon dioxide incubator using DMEM containing 2% fetal bovine serum as the maintenance medium until more than 85% of the cells showed cytopathic effects. The virus was harvested and recorded as ADV-PEDV SQ P2 virus.

3. The method for preparing a recombinant adenovirus of a PEDV S chimeric protein according to claim 2, It is characterized in that Step 3 The specific steps are as follows: HEK 293F cells were subcultured into 100 ml shake flasks using serum-free medium according to conventional methods, and the cell density reached 5 × 10 6 / ml was inoculated with ADV-PEDV SQ P2 virus, and after inoculation, the culture was placed at 37°C and 120rpm on an orbital shaker in a 5% carbon dioxide incubator. The cell status was observed daily and the cell viability was recorded. When the cell viability was lower than 30%, the culture bottle was placed in a -80°C refrigerator and repeatedly frozen and thawed three times, centrifuged at 12000rpm for 10 minutes, the supernatant was added to a 100KD ultrafiltration centrifuge tube, centrifuged at 4000rpm to 1 / 10 of the original volume, and then 0.1M phosphate buffer was added to the original volume, centrifuged at 4000rpm to 1 / 100 of the original volume, and finally glycerol was added at a ratio of 5:1, and the resulting aliquots were stored at -80°C, which were recorded as ADV-PEDV SQ P3 virus.

4. A recombinant adenovirus of a PEDV S chimeric protein, Features: It is prepared by the recombinant adenovirus preparation method of PEDVS chimeric protein according to any one of claims 1-3.

5. Use of a recombinant adenovirus of a PEDV S chimeric protein, Features: The recombinant adenovirus of the PEDV S chimeric protein prepared in claim 4 is used to prepare a PED vaccine.